New guidelines published in the Lancet Haematology provide healthcare professionals with evidence-based guidance on the treatment of people with Waldenström's macroglobulinaemia (WM).
The guidelines have been produced by the International Workshop for Waldenström’s macroglobulinaemia (IWWM), a panel of WM experts from across the world who meet every 2 years.
The last IWWM guidelines were published in 2016. The recommendations have been updated on the basis of the latest data from clinical trials. They include both chemotherapy and newer targeted drug treatments for WM, as well as new drugs being tested in clinical trials. The recommendations emphasise that the choice of treatment should be tailored to the individual.
Visit Lymphoma TrialsLink to read more about clinical trials or to search for clinical trials suitable for people with Waldenström’s macroglobulinaemia.
19 November 2020